US WorldMeds, LLC, a specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Myobloc (rimabotulinumtoxinB)
US WorldMeds, LLC, a specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Myobloc (rimabotulinumtoxinB)
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
